Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 5/20 | 0.69 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.69 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1792850 | 1.00 | CHRNA7 (0.69) | CHRNA7CHRNB2CHRNA4HRH3HTR3A | |
| SCHEMBL928223 | 0.82 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4HTR3ACHRNB4 | |
| SCHEMBL927548 | 0.78 | CHRNB2 (0.69) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1792587 | 0.78 | CHRNB2 (0.69) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL927665 | 0.78 | KCNH2 (0.67) | CHRNA7CHRNB2CHRNA4HRH3HTR3A | |
| SCHEMBL927667 | 0.78 | KCNH2 (0.67) | CHRNA7CHRNB2CHRNA4HRH3HTR3A | |
| SCHEMBL928530 | 0.77 | CHRNA7 (0.68) | CHRNA7HRH3HTR3ACHRNB4CHRNA3 | |
| SCHEMBL927670 | 0.76 | CHRNA7 (0.73) | CHRNA7CHRNB2CHRNA4HRH3HTR3A | |
| SCHEMBL928224 | 0.74 | CHRNA7 (0.82) | CHRNA7CHRNB2CHRNA4HRH3HTR3A | |
| Cadaverine Tartrate SCHEMBL1792402 | 0.73 | CHRNA7 (0.79) | CHRNA7CHRNB2CHRNA4HTR3ACHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | claimed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | claimed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | claimed |
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | CHRNA7 1/4885CHRNB2 7/4885CHRNA4 9/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | CHRNA7 1/4885CHRNB2 6/4885CHRNA4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.